Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.
作者信息
Cheng Pin-Nan, Yu Ming-Lung
机构信息
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2024 Apr;30(2):144-146. doi: 10.3350/cmh.2024.0115. Epub 2024 Feb 19.
Abstract
摘要
相似文献
1
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.
Clin Mol Hepatol. 2024 Apr;30(2):144-146. doi: 10.3350/cmh.2024.0115. Epub 2024 Feb 19.
2
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply.
Clin Mol Hepatol. 2024 Apr;30(2):272-273. doi: 10.3350/cmh.2024.0123. Epub 2024 Feb 21.
3
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22.
4
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22.
5
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lancet Gastroenterol Hepatol. 2020 May;5(5):441-453. doi: 10.1016/S2468-1253(19)30421-2. Epub 2020 Feb 20.
6
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Expert Rev Gastroenterol Hepatol. 2017 Nov;11(11):999-1008. doi: 10.1080/17474124.2017.1386554. Epub 2017 Oct 8.
7
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01064-18. Print 2018 Oct.
8
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Dig Dis Sci. 2023 Feb;68(2):665-675. doi: 10.1007/s10620-022-07657-8. Epub 2022 Aug 17.
9
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
10
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
BMC Infect Dis. 2021 Jun 14;21(1):567. doi: 10.1186/s12879-021-06237-x.
引用本文的文献
1
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B.
PLoS One. 2025 May 27;20(5):e0324897. doi: 10.1371/journal.pone.0324897. eCollection 2025.
2
Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide".
Clin Mol Hepatol. 2024 Oct;30(4):1031-1032. doi: 10.3350/cmh.2024.0228. Epub 2024 Apr 11.
3
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply.
Clin Mol Hepatol. 2024 Apr;30(2):272-273. doi: 10.3350/cmh.2024.0123. Epub 2024 Feb 21.
本文引用的文献
1
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
2
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Aliment Pharmacol Ther. 2024 Jan;59(2):230-238. doi: 10.1111/apt.17765. Epub 2023 Oct 16.
3
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.
Clin Mol Hepatol. 2024 Jan;30(1):16-36. doi: 10.3350/cmh.2023.0315. Epub 2023 Oct 4.
4
Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study.
Hepatol Int. 2024 Feb;18(1):138-154. doi: 10.1007/s12072-023-10576-z. Epub 2023 Sep 25.
5
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients.
World J Hepatol. 2023 Aug 27;15(8):964-972. doi: 10.4254/wjh.v15.i8.964.
6
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Am J Gastroenterol. 2024 Mar 1;119(3):486-496. doi: 10.14309/ajg.0000000000002468. Epub 2023 Aug 9.
7
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study.
Am J Gastroenterol. 2023 Jun 1;118(6):1001-1009. doi: 10.14309/ajg.0000000000002074. Epub 2022 Oct 25.
8
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Clin Mol Hepatol. 2022 Apr;28(2):254-264. doi: 10.3350/cmh.2021.0314. Epub 2021 Dec 28.
9
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
BMC Infect Dis. 2021 Jun 22;21(1):595. doi: 10.1186/s12879-021-06304-3.
10
Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load.
JHEP Rep. 2019 Mar 19;1(1):9-16. doi: 10.1016/j.jhepr.2019.02.002. eCollection 2019 May.
Zotero 插件